



Claudia Bogado

Contact Information	<ul style="list-style-type: none">• Av Medrano 134 floor 6 Caba. Bs As. Argentina. Zip Code C1179AAB.• Phone 054 011 4983 1589.• Email: claudiabogado@imoba.com.ar
Education	<ul style="list-style-type: none">• Disposición 6677/10 ANMAT, Imoba 2018• Good Clinical Practice, Eli Lilly jun 2018.• Good clinical Practice, The Global Healt Network Oct 2021.• Diploma in Good Practices in Biomedical Research. University of San Pablo.Tucumán. August 2020 to July 2021 (238 hours).
Current employment information	<ul style="list-style-type: none">• Investigaciones Médicas IMOBA SRL• Av. Medrano 134 floor 6 CABA• Study coordinator from 2018 to present.
Clinical studies in the last 5 year	<ul style="list-style-type: none">➤ I8B-MC-ITRN Prospective, double-blind, randomized study of LY900014 compared with insulin Lispro in combination with insulin Glargine or insulin Degludec in adults with type 2 diabetes PRONTO-T2D. From 2018 to 2019. Phase III. Eli Lilly. Studies coordinator.➤ I8B-MC-ITRM Prospective, double-blind, randomized study of LY900014 compared with Lispro insulin with an open-label treatment group with postprandial LY900014 in combination with insulin Glargine or insulin Degludec in adults with type 1 diabetes PRONTO-T1D. From 2018 to 2019. Phase III. Eli

Lilly. Studies coordinator.

- CLCZ696D2301 Multicenter, randomized, double-blind, parallel-group, active-controlled study to evaluate the efficacy and safety of LCZ696, compared to valsartan, on morbidity and mortality in participants with heart failure (Class II-IV of NYHA) and preserved ejection fraction. From 2018 to the present. Phase 3. Novartis. Studies coordinator.
- 1002-043 (CLEAR), entitled "Randomized, double-blind, placebo-controlled study to evaluate the effects of bempedoic acid (ETC-1002) on the occurrence of major cardiovascular events in patients with cardiovascular disease or at high risk of developing it, who do not tolerate statins
- Protocol H9X-MC-GBGL "A randomized, double-blind, parallel-arm study to study the efficacy and safety of investigational doses of Dulaglutide when added to Metformin in patients with type 2 diabetes mellitus." From 2018 to December 2019. Phase III. Coordinator of clinical studies. Eli Lilly.
- K-877-302 Prominent Pemafibrate to reduce cardiovascular outcomes by lowering triglycerides in patients with diabetes. From 2018 to the present. Phase III. Quintiles. Studies coordinator.
- I8F-MC-GPGM Efficacy and safety of Ly3298176 once a week vs insulin glargine in patients with type 2 diabetes and high cardiovascular risk. From March 2018 to July 2021. Phase III. Eli Lilly. Study coordinator.
- I8F-MC-GPGH: Phase 3 open-label, randomized study comparing the effect of LY3298176 vs titrated insulin Degludec on the glycemic control of pts. with type 2 diabetes. Eli Lilly. From July 2018 to April 2021. Phase III. Eli Lilly. Study coordinator.
- I8F-MC-GPGL: Randomized, open-label, phase 3 trial, comparing the efficiency and safety of Tirzepatide vs Semaglutide once a week as an add-on therapy to metformin in patients with type 2 DBT. Eli Lilly. From July 2019 to May 2021. Phase III. Eli Lilly. Study coordinator.
- FINEART s-HF-(Bayer) Multicenter, randomized, double-blind, placebo-controlled parallel group study to evaluate the efficacy and safety of finerenone in morbidity and mortality in patients with Heart Failure (NYHA II-IV) and fraction left ventricular ejection $\geq 40\%$ (LVEF $\geq 40\%$). Phase 3. Study

Coordinator. From Oct 2020 to present.

- I8H-MC-BDCL A Phase 2 parallel, comparator- Controlled Trial to Evaluate the Safety and Efficacy of LY3209590 in Insulin- Native with Type 2 Diabetes Mellitus. Eli Lilly. Study coordinator. From Nov 2020 to present.

- I8F-MC-GPHM Efficacy and SAfefty of Tirzepatide Once Weekly vs Placebo after an intensive Lifestyle Program participants without Type 2 Diabetes who have Obesiy or are Overweight with weight- related Comorbidities: Randomized Double Blind, Placebo Controlled Trial. Study coordinator. From April 2021 to present.

- I8F-MC-GPHD Arandomized, phase 3, open label Trial comparing the effect of the addition of tirzepatide once weekly vs insulin lispro (U100)Three times daily in participants with type 2 diabetes inadequately controlled on insulin glargine (U100) with or without metformin. Study coordinator. From Dec 2020 to present.

Signature:

Date: